Novartis Venture Fund — Full Portfolio

Aileron Therapeutics is a clinical-stage biopharmaceutical company developing peptide and protein-based therapies for rare lung and fibrosis diseases.

BiotechCambridge, US

MAManuel Aivado(Executive Officer)inBrian Windsor(President and Chief Executive Officer; Director)in

BoardCaleb Winder(Director)inSeth L. Harrison(Director)Reinhard J. Ambros(Director)Joseph A. Yanchik III(Executive Officer, Director)in

Co-investorsEXExcel Venture Management

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

GWGregory Winter(Director)inNCNIGEL CROCKETT(Executive Officer)inNKNICHOLAS KEEN(Executive Officer)SASANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAHAhren Innovation CapitalASAstellas Venture Management LLCCACambridge Innovation CapitalDEDementia Discovery FundLOLongwood FundRIRidgeback Capital+4 more

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.

BiotechHealthtechMedical DevicesMelbourne, AU

SPSara Prickett(Co-founder)in

Co-investorsBRBreakthrough VictoriaTETenmileUNUniSeed Pty Ltd.

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

JBJane Buckner(Scientific Co-founder (President, Benaroya Research Institute))CPChandra Patel(Co-founder & SVP, Research and Development Operations)inDRDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)ASAndy Scharenberg(Scientific Co-founder, SAB Chair)AWAndy Walker(President and CEO)inTWTom Wickham(Chief Scientific Officer)

Co-investorsOROrbiMedJDJDRF T1D FundRARA Capital

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

PLPatrick Loustau(President and Chief Executive Officer)in

Co-investorsSASanofi VenturesFOForbionVEVersant Ventures

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.

BiotechDeep TechMedical DevicesBurlington, US

KCKLEEM CHAUDHARY(Executive Officer, Director, Promoter)inK(Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)KCKleem Chaudhary, PhD(President & CEO)

BoardJOHN GUSTOFSON(Director)LBLAURA BRASS(Director)inLTLAURA TADVALKAR(Director)in

Co-investorsDRDroia VenturesEIEisai Innovation, Inc.RARA Capital

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

NMNeil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inCSClaus Sundgreen(Chief Medical Officer)inPTPaul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCRCriteria Bio VenturesSVSV Health InvestorsBRBritish Business BankM M VenturesDEDementia Discovery FundOMOmega Funds

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

DZDavid Zacks(Co-Founder & Chief Scientific Officer)inDEDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)JKJohn K Freshley(Executive Officer, Director)inJAJeffrey A Jamison(Executive Officer)in

BoardAFAaron Fletcher(Director)in

Co-investorsEXExSight VenturesINInvest MichiganVIVisionary VenturesBIBios PartnersINInFocus Capital Partners, LLCJOJohnson & Johnson Innovation – JJDC+3 more

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

BRBotond Roska(Researcher (M.D., Ph.D.))BGBence György(IOB Assistant Professor & Head of Clinical Translation)inKHKatherine High(CEO)in

Co-investorsARARCH Venture PartnersBIBioGeneration VenturesF-F-Prime CapitalGVGV (Google Ventures)

Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.

BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Jim Wells(Co-founder, Scientific Advisory Board Chair)KMKristine M Ball(Executive Officer, Director)inZHZachary Hill(Executive Officer, Director)in

BoardNisha Marathe(Director)DADavid Allison(Director)inKGKeno Gutierrez(Director)in

Co-investors5A5AM VenturesRORoche Venture FundVEVersant VenturesBIBioGeneration VenturesWEWestlake Village BioPartners

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

DVDr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsASAsabys PartnersRORoche Venture FundSASanofi VenturesYSYsios CapitalCRCriteria Bio VenturesNENew Enterprise Associates (NEA)+3 more

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHEHealthCapKUKurma PartnersRORoche Venture FundYSYsios CapitalCOColumbus Venture PartnersEUEurazeo+1 more

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)PYPaul Yaworsky, PhD(CSO)inRBRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Board seatAKAnja Koenig· per SEC Form D

Co-investorsAGAgent CapitalGIGimvLOLongwood FundMIMission BiocapitalONOno Venture Investment, Inc.PFPfizer Venture Investments+5 more

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

ESEmmanuel Simons(Executive Officer, Director)WSwilliam sewell(Founder)in

BoardEMEd Mathers(Director)inKPKush Parmar(Director)in

Co-investors5A5AM VenturesECEcoR1 CapitalNENew Enterprise Associates (NEA)PIPivotal Life SciencesRARA CapitalSOSofinnova Ventures+2 more

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

IGIlan Ganot(CEO)inBMBenit Maru(CMO)MVMatthias Van Woensel(CSO)in

Co-investorsDRDroia VenturesFRFrazier Life SciencesRVRV Invest GmbHFRFrazier Healthcare PartnersMPMPM BioImpactRTRTW Investments L.P.+1 more

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

LMLouise Modis(Chief Executive Officer)inMPMartin Pass(Chief Development Officer)inGBGiles Brown(Executive VP Drug Discovery)in

Co-investorsADAdvent Life SciencesSVSV Health InvestorsDEDementia Discovery FundEUEuropean Investment FundFOForbionGIGilde Healthcare+2 more

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

TThaminda(Chief Business Officer)inLPLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsPFPfizer Venture InvestmentsPOPontifax Venture CapitalFOForbion

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsANAndera PartnersDEDementia Discovery FundM M VenturesPFPfizer Venture InvestmentsRARA CapitalSOSofinnova Partners+6 more

Arvada Therapeutics is a biotechnology company focused on drug development for rare and degenerative diseases, working across preclinical research and clinical stages.

BiotechHealthtechLongevity

SFShiYin Foo(Founder and CEO)Ryan Tyler(Co-founder and SVP of Preclinical Research)

Co-investorsPIPillar VC

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

JRJane Rhodes(Chief Executive Officer)inMIMagnus Ivarsson(Chief Scientific Officer)inHPHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

Co-investorsDEDementia Discovery FundMPMPM BioImpactSVSV Health InvestorsUCUCL Technology FundALAlbionVC

Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.

BiotechDeep TechHealthtechMedical Devices

Co-investorsF-F-Prime CapitalRIRiverVest Venture PartnersSASanofi VenturesABabrdn plcEQEQT Life Sciences

Atalanta is a web agency that designs and builds custom websites, mobile applications (iOS/Android), bespoke CRM tools, and provides UX/UI design and SEO services.

Developer ToolsMarketing TechSaaSAngers, FR

Antoine Chérel(Founder)

Co-investorsABAbstract Ventures

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechHealthtechMedical DevicesWatertown, US

RMRichard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)

BoardRoy Amariglio(Director)NONick Olsen(Director)inSSStephen Squinto(Director)inMichal Silverberg(Director)in

Co-investorsDEDeep InsightDEDelos CapitalOROrbiMedARARC VENTURESINInsight Partners

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)SCScott Clarke(Chief Executive Officer)inPGPeter Garcia(Chief Financial Officer)SRSujata Rao(Chief Medical Officer)inSRStefan Ries(Chief Scientific Officer and Head of Munich Site)inAGAndrea Goddard(Chief Technical Officer)in

Co-investorsJEJeito CapitalBIBioqube VenturesFOForbionBABayern KapitalBIBioGeneration VenturesCACanaan Partners+2 more

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.

BiotechHealthtechMedical DevicesOss, NL

RCRenato Chirivi(Co-founder (former CSO))in

BoardPaul Peter Tak(Chair of the Board)

Co-investorsBIBioGeneration VenturesPUPureos BioventuresSESeventure PartnersFOForbionJOJohnson & Johnson Innovation – JJDCBOBOM+1 more

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

JFJohn Ford(Co-founder)inMGMartin Gosling(Founder)in

Co-investorsEPEpidarex CapitalVEVersant VenturesFOForbionIPIP GroupPAPanakes Partners

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

ALAnn Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSBSamuel Bjork(Director)inACAlexandra Cantley(Director)inSMSeiji Miyahara(Director)in

Co-investorsAVAvego BioScience CapitalGVGV (Google Ventures)MIMission BiocapitalRORoche Venture FundSASamsara BioCapitalTATaiho Ventures, LLC+4 more

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

TWTim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNRNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B3B Future Health FundALAlbionVCBIBioGeneration VenturesEPEpidarex CapitalGLGlobal BioAccess FundUCUCL Technology Fund

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)ASAlan Saghatelian, PhD(Co-Founder)DLDavid LiuinASAlan Saghetelian

Co-investorsNENewpath PartnersCRCRV (Charles River Ventures)NENextech InvestRARaptor GroupSASamsara BioCapitalBIBiotechnology Value Fund+1 more

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsADAdvent Life SciencesAIAisling CapitalAMAMR Action FundASAstellas Venture Management LLCBRBrace PharmaSOSofinnova Partners+4 more

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

BoardCPCary Pfeffer(Executive Officer, Director)inRTRobert Tepper(Director)inCHCharles Homcy(Director)

Co-investorsTHThird Rock Ventures

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBHBM Healthcare InvestmentsHBHBM PartnersLGLG Technology VenturesOROrbiMedPOPontifax Venture CapitalSRSR One Capital Management+4 more

Co-investorsINInnovestor VenturesM M VenturesSUSunstone Capital

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.

BiotechDeep TechHealthtechBasel, CH

TBTarig Bashir(Chief Executive Officer (CEO))inJWJens Würthner(Chief Medical Officer (CMO))FZFrank Zenke(Chief Scientific Officer (CSO))in

Co-investorsM M VenturesPFPfizer Venture InvestmentsOMOmega Funds

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

BoardLBLaura Brass(Director)inKWKai Wucherpfennig(Director)

Co-investorsAGAgent CapitalDCDC Investment PartnersLILifelinkLOLongwood FundMEMedical Excellence CapitalONOno Venture Investment, Inc.+5 more

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)CKChrister Köhler(Founding Director)inKees Been(Chief Executive Officer)inJWJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYSYsios CapitalFOForbionSUSunstone Capital

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

DRDavid Reynolds(Co-founder & CEO)inCBCaroline Benn(Co-founder & CSO)in

Co-investorsDEDementia Discovery FundSVSV Health InvestorsFOForbion

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)HSHenry Skinner(Director)inVikas Goyal(Director)RPRaj Parekh(Director)in

Co-investorsADAdvent Life SciencesGUGurnet Point CapitalRORoche Venture Fund

BiotechDublin 1

Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)

Co-investorsAIAisling CapitalECEcoR1 CapitalFRFrazier Life SciencesLOLongitude CapitalMEMESA VERDE VENTURE PARTNERS

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

AI & Machine LearningBiotechDeep Tech

Kamil Tamiola(Founder)

Co-investorsBEBessemer Venture PartnersHOHoxton VenturesWAWalden CatalystF-F-Prime CapitalFOFounders FactoryFOFounders Factory NY

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

PRPablo Rojas(Founder)inRafael Casabianca

Co-investorsY Y CombinatorDIDigitalis VenturesDRDroia VenturesFOForbionGLGlilot Capital PartnersGLGlobal Founders Capital+7 more

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

BJBrent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDRDroia VenturesDIDigitalis VenturesFOForbionLILightspeed Venture PartnersMPMPM BioImpactVIVida Ventures+1 more

Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsADAdvent Life SciencesNONovo Holdings

BiotechGreenwhich, US

WDWendy DiCicco(Ms. DiCicco is the Secretary and Treasurer of the Issuer.)inArthur Feldman(Director)Magdalene Cook(Executive Officer, Director)Campbell Murray(Director)Edward J. Benz, Jr.(Director)TNThomas Needham(Director)in

Co-investorsBIBioAdvanceBRBroadview VenturesELElysia CapitalINInnogest CapitalNENew Leaf Venture Partners

BiotechLexington, US

VMVictoria M. Richon(Executive Officer, Director)in

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAVAvego BioScience CapitalOUOUP (Osage University Partners)PEPeregrine VenturesABAbbVieDEDeerfield Management CompanyJJJJDC+3 more

PSS Solutions is an independent consulting and advisory group focused on intellectual property, helping organizations improve and manage their IP operations.

BiotechEnterprise SoftwareLegalTechPropTech

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

EMEric Murphy(Chief Executive Officer, Co-Founder, & Director)in

Co-investorsASAstellas Venture Management LLCDCDCVC (Data Collective)DCDCVC BioFRFrazier Life SciencesLOLongwood FundOROrbiMed+2 more

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBIBifLILightstone VenturesNENew Enterprise Associates (NEA)YSYsios CapitalCLClarus VenturesGIGilde Healthcare+1 more

HealthtechLexington, US

Simon Williams(Executive Officer, Director)JHJohn Hartnett(Executive Officer)

BoardRBRichard B. Emmitt(Director)inEdward M. Giles(Director)Anthony J. Sinskey(Director)

Co-investorsTHThe Vertical Group

BiotechCarlsbad, US

John Gordon Foulkes(Executive Officer, Director)

BoardMette Agger(Director)Peter Bisgaard(Director)Giovanni Ferrara(Director)Tiba Aynechi(Director)Michael Ross(Director)

Co-investorsSVSV Health InvestorsSVSV Life Sciences

Viamet provides a resource for people to organize questions and conduct research about medical travel, provider verification, care coordination, and health-related travel planning.

Digital HealthHealthtechTravel & HospitalityWellness & Fitness

Co-investorsASAstellas Venture Management LLCHAHatteras Venture PartnersLILilly VenturesWOWoodford Investment Management